Psychedelic drug research, driven by the promising results obtained from controlled clinical trials, is experiencing a revival. There is a renewed confidence that treatments derived from psychedelics will significantly improve the quality of life for patients suffering from a wide range of psychiatric disorders ranging from depression and anxiety to post-traumatic stress disorder.
In this webinar hear about lessons learned, recent advances, and the promise of future metal health therapeutics inspired by many years of research on psychedelics. The expert panel will discuss their utilization of emerging drug discovery, design and development methods and strategies critical to accelerating the delivery of new treatments.
David Nichols is a Professor Emeritus of Pharmacology at Purdue University, where he was also the Previously the Robert C. and Charlotte P. Anderson Distinguished Chair in Pharmacology. In addition to his academic career, David is the founding president of the Heffter Research Institute.
Dr. Nichols received a Bachelor of Science degree from the University of Cincinnati, a PhD degree from University of Iowa and completed postdoc work at the University of Iowa.
Charles Nichols is a Professor of Pharmacology at Louisiana State University's Health Sciences Center in New Orleans. Prior to LSU, Charles was a Research Assistant Professor of Pharmacology at Vanderbilt University.
Dr. Nichols received a Bachelor of Science degree from Purdue University and PhD from Carnegie Melon University with Postdoctoral work at Vanderbilt University.
Sam Banister is the Co-founder and Chief Scientific Officer of Psylo, an Australian company that develops next-generation therapeutics inspired by psychedelics from nature. In addition, he serves as a scientific advisor to several biotech firms. Prior to these roles, Sam was Team Leader in Medicinal Chemistry at Brain and Mind Centre.
Dr. Banister has a Bachelor and PhD degrees from University of Sydney and Postdoctoral work at Stanford University.